Competitive Topology

This is the most translationally advanced cluster in the sample, anchored by FDA-approved 177Lu-PSMA-617 (Pluvicto) as a clinical reference point, with active Phase 1 dose-escalation trials at multiple sites and a dense patent portfolio covering PSMA chelation chemistry and ligand scaffolds (15 patents identified, predominantly from JOHNS HOPKINS UNIVERSITY); near-term commercial activity centers on reducing off-target toxicity (salivary gland, renal) and on next-generation ligand variants. **Confidence: High** - Evidence: approximately 18 projects across UCSF, MSK, Johns Hopkins, U Michigan, Fred Hutchinson, NCI, and two commercial entities (TRIPILL BIOTECHNOLOGY and CANCER TARGETED TECHNOLOGY), corroborated by 4 clinical trials (Phase 1 Lu-177-PSMA dose escalation, SPECT dosimetry trials) and 12 PSMA-specific patents.

Alpha-emitter theranostic pairing (notably Pb-203/Pb-212, Ac-225, Ra-223, and Bi-213 platforms) is progressing from preclinical optimization toward early clinical translation, with one Early Phase 1 trial (212Pb-Pentixather) identified in the sample and active chelation chemistry development; commercial readiness is limited by isotope supply chain constraints and the absence of approved alpha-emitter agents for prostate cancer beyond Ra-223, though the Pb-203/212 theranostic pair shows the clearest near-term translational trajectory. **Confidence: High** - Evidence: approximately 12 projects across MSK, U Iowa, Washington U, Johns Hopkins, UCSB, SUNY Stony Brook, Cornell, U Pittsburgh, and QSCINT IMAGING SOLUTIONS, corroborated by 1 early-phase clinical trial and isotope-specific chelator patents.

Computational dosimetry and deep learning treatment planning for RPT represent an active but relatively narrow segment of the sample, with clinical-stage SPECT/CT dosimetry protocols running at UNIVERSITY OF MICHIGAN and JOHNS HOPKINS and Yale's deep learning PSMA dosimetry project targeting clinical workflow integration; commercialization pathways likely involve software-as-medical-device regulatory classification, and no dedicated commercial entities appear within the NIH-linked sample for this approach. **Confidence: Medium** - Evidence: 4-5 projects concentrated across U Michigan, Yale, and Johns Hopkins, corroborated by 2 clinical trials explicitly focused on dosimetry optimization (SPECT imaging for dosimetry, SPECT/CT for Lu-177-PSMA-617 therapy).

Combinations of targeted radionuclide therapy with tumor vaccination, checkpoint inhibitors, or CAR-T cell priming represent one of the fastest-growing strategic directions in the sample, with multiple projects explicitly mechanistically investigating immunogenic cell death, T-cell expansion, and microenvironment reprogramming after RPT; a Phase 1 trial of Y-NM600 with anti-PD-1/PD-L1 at UNIVERSITY OF WISCONSIN is the primary clinical signal, and commercialization timelines are likely 5-8 years given the mechanistic complexity and need for combination IND strategies. **Confidence: High** - Evidence: approximately 10 projects across UW-Madison, UCSF, UCLA, U Colorado Denver, and NCI, corroborated by 2 patents (TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION from U Wisconsin) and 1 active Phase 1 immuno-RPT combination trial.

Projects developing new targeting vectors beyond PSMA (including DLL3-antibody conjugates, CD46-directed agents, TGF-beta theranostics, neurotensin receptor-1 agents, Meitner-Auger PARP1 ligands, and next-generation chelator scaffolds for Lu-177, Y-90, and alpha emitters) represent the most heterogeneous and early-stage cluster in the sample; commercial readiness is low for most constituents given that the majority are preclinical, though MOLECULAR TARGETING TECHNOLOGIES holds an active project targeting lung cancer with Lu-177 EBRGD and a few antibody-chelator conjugate platforms are approaching IND-enabling studies. **Confidence: Medium** - Evidence: approximately 8-10 projects spanning MSK, UCSF, Illinois Tech, Cornell, UW-Madison, Molecular Targeting Technologies, Washington U, and UT Southwestern, with limited patent or trial corroboration for the specific novel-vector subcomponents; confidence is medium due to project count and multi-org spread but absence of cross-source validation for most individual vectors.